Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer

Cancer Investigation

Volumn 27, Issue 4, 2009, Pages 391-396

  Araújo, António M F ^a   Mendez, Jose C ^b   Coelho, Ana L ^a   Sousa, Berta ^a   Barata, Fernando ^c   Fiqueiredo, Ana ^c   Amaro, Teresina ^a   Azevedo, Isabel ^a   Soares, Marta ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Centro Oncologico de Galicia   (Spain)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Celecoxib; Chemotherapy; Cox 2 inhibitors; Extensive stage; Small cell lung cancer

Indexed keywords

CELECOXIB; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNCONSCIOUSNESS; URTICARIA; CANCER STAGING; DISEASE COURSE; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PORTUGAL; SPAIN; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; ETOPOSIDE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PORTUGAL; PYRAZOLES; QUALITY OF LIFE; SMALL CELL LUNG CARCINOMA; SPAIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 65249102331     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802232756     Document Type: Article

References (41)

1. Greenlee, R.T.; Murray, T.; Bolden, S.; etal. Cancer statistics, 2000. CA Cancer J Clin 2000, 50, 7-33.
2. Osterlind, K.; Ihde, D.C.; Ettinger, D.S.; etal. Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 1983, 67, 3-9.
3. Aisner, J. Extensive-disease small cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 1996, 14, 658-665.
4. Roth, B.J.; Johnson, D.H.; Einhorn, L.H.; et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: phase III trial of Southeastern Cancer Study Group. J Clin Oncol 1992, 10, 282-291.
5. Fukuoka, M.; Furuse, K.; Saijo, N.; et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these two regimens in small-cell lung cancer. J Natl Cancer Inst 1991, 83, 855-861.
6. Bozcuk, H.; Artac, M.; Ozdogan, M.; et al. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A meta-analysis of the published randomized controlled trials. Cancer 2005, 104,2650-2657.
7. Kellof, G.J.; Steele, V.E.; Sigman, C.C. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. In: Harris, R.E. (ed.). COX-2 Blockade in Cancer Prevention and Therapy. New Jersey, USA: Humana Press, 2003, 279-300.
8. Mitchell, J.A.; Akarasereenont, P.; Thiernermann, C; et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994, 90, 11693-11697.
9. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971,231, 232- 235.
10. O'Neil, G.R; Ford-Hutchison, A.W. Expression of mRNA for cycIooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993, 330, 156-160.
11. Smith, W.L; Meade, E.A.; DeWitt, D.L. Pharmacology of prostaglandin endoperoxide synthase isozymes 1 and 2. Ann NY Acad Sci 1994, 14,136-142.
12. Markowitz, S.D. Aspirin and colon cancer. N Engl J Med 2007, 356, 2195-2198.
13. Chute, J.R; Chen, T; Feigal, E.;etal.Twentyyearsofphasellltrials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999, 17,1794-1801.
14. Wolff, H.; Saukkonen, K.; Anttila, S.; et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58,4997-5001.
15. Subbaramaiah, K.; Zakin, D.; Dannenberg, A. Inhibition of cyclooxygenase; a novel approach to cancer prevention. Exp Biol Med 1997, 216, 201-210.
16. Graul, A.; Martel, A.M.; Castanar, J. Celecoxib. Drugs Future 1999, 22,711-714.
17. Soslow, R.A.; Dannenberg, A.J.; Rush, D.; et al. COX-2 is expressed in human colonic and mammary tumours. Cancer 2000, 89, 2637-2645.
18. Alshafie, G.A.; Abou-lssa, H.M.; Seibert, K.; et al. Chemothera- peutic evaluation of celecoxib, a cyclooxygenase-2 inihbitor, in a rat mammary tumour model. Oncol Rep 2000, 7,1377-1381.
19. Abou-lssa, H.; Alshafie, G. Celecoxib: a novel treatment for lung cancer. Exp Ver Anticancer Ther 2004, 4, 725-734.
20. Grosch, S.; Tegeder, I.; Niederberger, E.; etal. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15, 2742- 2744.
21. Xu, X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs 2002, 13,127-137.
22. Frantz, B.; O'Neill, E.A. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995, 270, 2017-2019.
23. Huang, C; Ma, W.Y; Hanenberger, D.; et al. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1- luciferase transgenic mice. J Biol Chem 1997, 272, 26325-26331.
24. He, T.C.; Chan, T.A.; Vogelstein, B.; et al. PPARdelta is an APC- regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99, 335-345.
25. Wick, M.; Hurteau, G.; Dessev, C; et al. Peroxisome proliferator- activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002, 62, 1207-1214.
26. Cao, Y; Pearman, A.T.; Zimmerman, G.A.; et al. Intracellular un- esterefied arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000, 97, 11280-11285.
27. Sanchez-Alcazar, J.A.; Bradbury, D.A.; Pang; et al. Cyclooxyge- nase (COX) inhibitors induce apoptosis in non-small-cell lung cancer through cyclooxygenase-independent pathways. Lung Cancer 2003,40, 33-44.
28. Aaronson, N.K.; Ahmedzai, S.; Bergmam, B.; et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
29. Bergmam, B.; Aaronson, N.K.; Ahmedzai, S.; et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trialsE-ORTC Study Group on Quality of Life. Eur J Cancer 1994, 30A, 635-642.
30. Kaasa, S.; Bjordal, K.; Aaronson, N.K.; et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995, 31A, 2260-2263.
31. Bergmam, B.; Sullivan, S.; Sorenson, S. Quality of life during chemotherapy for small cell lung cancer: a longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile. Acta Oncol 1992, 31, 19- 28.
32. Fleming, T.R. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38,143-151.
33. Fitzgerald, G.A. Coxibs and cardiovascular disease. N Engl J Med 2004, 351,1709-1711.
34. Solomon, D.S.; McMurray, J.J.V.; Pfeffer, M.A.; et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352, 1071- 1080.
35. Kerr, D.J.; Dunn, J.A.; Langman, M.J.; et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007, 357, 360-369.
36. Hesketh, P.J.; Chansky, K.; Israel, V.; etal. Phase II study of gemc- itabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol 2007, 2, 440-444.
37. De Marinis, R; Nelli, R; Lombardo, M.; et al. A multicenter, randomized, phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005, 103,772- 779.
38. Johnson, D.; Csiki, I.; Gonzalez, A.; et al. Cyclooxygenase-2 (COX- 2) inhibition in non-small-cell lung cancer (NSCLC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003, 22, 640 (Abstr. 2575).
39. Edleman, M.J.; Watson, D.M.; Wang, X.; et al. Eicosanoid modulation in advanced non-small-cell lung cancer (NSCLC): CALGB 30203. J Clin Oncol 2006, 24, 370s (Suppl. Abstr. 7025).
40. Reckamp, K.L.; Krysan, K.; Morrow, J.D.; et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small-cell lung cancer. Clin Cancer Res 2006, 12, 3381-3388.
41. Csiki, I.; Johnson, D. Did targeted therapy fail cyclooxygenase too? J Clin Oncol 2006, 24, 4798-4800.